Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

The recent launch of BILDYOS® and TUZEMTY®, biosimilars to PROLIA and XGEVA, marks a significant step forward in expanding Organon Canada's biosimilars portfolio to eight products across five therapeutic areas. These biosimilars aim to provide more accessible and affordable treatment options for patients needing denosumab injections, which are commonly used for osteoporosis and bone cancer-related issues. The move is crucial as it underscores the growing trend toward offering more cost-effective alternatives to expensive biologic drugs, potentially reducing healthcare costs and improving patient outcomes.